INTRODUCTION
The 5th International Congress of Multiple Sclerosis was once more held in Porto, from February 14th to 16th, 2019. In line with the rapid development of science, technology and lifestyles, the 2019 Congress focused on the encounter between basic and clinical sciences. The intensive program covered a wide range of topics including the most recent advances regarding demyelinating diseases, their underlying molecular mechanisms, treatment advances and a broad view of the management of multiple sclerosis (MS) worldwide. The latest findings and updates on these key issues were discussed by leading experts in the field in four oral sessions entitled 'MS in the World, the World of MS', 'Maths and Physics in MS', 'Hot Topics Grand Round', and 'From Bench to Bedside'. Furthermore, the selection of oral and poster presentations included in the current supplementary issue of Neurology and Therapy provided a forum for attendees to share, debate and analyze the most recent advances about the etiopathogenesis, therapeutic innovations, unmet needs and future challenges in the area of MS. Introduction: Fatigue in multiple sclerosis (MS) is primary and is aggravated by secondary causes and environmental factors. Several cross-sectional studies with application of the fatigue severity scale (FSS) in MS confirm the high frequency of fatigue in this disease, regardless of disability. Persistent fatigue has a lack of studies, because it requires studies with longitudinal design. A new fatigue scale for MS was recently validated for the Portuguese language, NFIS-MS/BR. Objectives: To evaluate subjective fatigue in a longitudinal study in MS patients applying two scales. Methodology: Patients attended consecutively at Hospital da Lagoa (Rio de Janeiro) between April and June 2017 with relapsing-remitting MS, EDSS from zero to 2.5, out of the relapse and without comorbidities were invited to participate in the study.
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Evaluation of Persistent Fatigue in Multiple Sclerosis
Clinical data were collected in medical records. The questionnaires of the FSS and NFIS-MS/BR scales were completed in three interviews with a three-month interval. Persistent fatigue was defined by fatigue scores in FSS (C 28) or NFI-MS/BR (C 30) in the three collections and sporadic fatigue in at least one of these collections. Results and Conclusions: The total of 38 patients who answered the scales in the first interview, fatigue was identified in 74.4% by FSS and 64% by NFIS-MS/BR. Twenty-six patients who attended the three interviews, fatigue by FSS was persistent in 54% of the patients, sporadic in 38% and 8% without fatigue. According to NFI-MS/BR fatigue was persistent in 47% of the patients, sporadic in 33% and 20% without the symptom. Conclusion: Fatigue occurs in the majority of patients with MS with mild disability, being persistent in about 50% of the cases. FSS showed greater sensitivity for fatigue identification, but the NFIS-MS/BR presents items that best describes the characteristics of fatigue in MS. 
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Introduction: Multiple sclerosis (MS) is an inflammatory, demyelinating and unpredictable disease, which its origin and treatment is yet unknown. It is the chronic neurological disease that more affects young adults, at working age, and might develop into situations of varying levels of disability. Objectives: This study's main objective was to understand the perception of quality of life (QOL), from vulnerability to stress and social support of people with MS, as well as the socio-demographic, clinical and psychosocial influences. Methodology: It was conducted a cross-sectional, descriptive-correlational study, of quantitative nature, where 54 MS patients attended, most of them were women (61.1%), married (72.2%), with an age average of 42 years, employed (37.0%), with an age average of 33 years old at the beginning of the disease. To measure the variable the following instruments were used: Social-Demographic/Clinic Questionnaire, Multiple Sclerosis Scale and Quality of Life, Barthel Index, Scale of Vulnerability to Stress and Social Support Scale.
Results and Conclusions:
The MS patients between 20 and 31 years, employed, with younger age at the beginning of the disease, without sequelae and with reduced level of dependence have better physical functioning; the patients that have associated disease are the one's who report a greater bodily pain and a better cognitive functioning; the one's that show higher functional capacity have better social skills; the one's who carry out rehabilitation have better mental health; MS patients between 56 and 67 years with a higher age at the beginning of the disease are the one's who manifest worse sexual functioning; the one's who have better general QOL are those who are satisfied with their jobs. There are also significant influences between QOL and all factors of vulnerability to stress, as well as between QOL and all factors of social support (in relation to psychosocial variables). Introduction: Studies on health-related quality of life (HRQoL) describe a reduction in all Short Form (SF)-36 scores in patients with multiple sclerosis (MS) with different levels of disability. Objectives: Here we analysed HRQoL in patients with MS without disability and compared it with that in healthy controls, as well as investigated the impact of subclinical depression and fatigue in the physical and mental domains.
Methodology: This is a cross-sectional study of Brazilian patients from Rio de Janeiro with relapsing-remitting MS who had Extended Disability Status Scale scores of 0-1.5. Instruments used included SF-36 to assess HRQoL, Beck Depression Inventory to assess depression, Fatigue Severity Scale and 6-minute walk test to assess ambulation and Paced Auditory Serial Addition Task to assess cognition, and the results were compared between patients with MS and healthy controls. Multiple linear regression models were applied in each of the eight SF-36 domains to analyse the influence of demographic and clinical factors on the reduction of HRQoL. Methodology: This is a cross-sectional case control study of a cohort in follow-up over the last 10 years. Results and Conclusions: Results: Data from 50 patients and 50 controls were obtained. The female sex was more frequent. The mean age of the two groups is found in the 5th decade of life. In the group of patients the median EDSS was 2, ranging from 0 to 8.5 and the average disease time was 8.7 years (± 7.5 years). There was no significant difference between the mean serum levels of vitamin D between the groups studied. However, the majority of participants in both groups had serum levels of vitamin D below normality. There was also no difference between these two groups when assessing the time of daily exposure to sun Introduction: The influence of gut microbiota in host immune and inflammatory status has been pointed out as an important predisposing factor in multiple sclerosis (MS) and other inflammatory diseases.
Objectives: In this work, we investigated the differences in the gut microbiota of a cohort of Portuguese MS patients and healthy controls. Methodology: MS patients (n = 27) and HC (n = 26) were recruited from the MS Clinic of our Hospital. Feces were collected and DNA extracted using a commercial kit. The V3-V4 regions of the 16S rRNA gene were amplified and sequenced using the MiSeq platform from Illumina. Amplicon sequence variants (ASVs) were identified with DADA2. Taxonomic composition was assigned using the Silva database. Wilcoxon test and False Discovery Rate were applied to identified microbiota differences (i.e. genera, ASVs, Shannon diversity).
The richness (number of ASVs) and diversity (Shannon index) of the gut microbiota were similar between MS patients and HC. The overall microbiota structure was different among HC and MS patients at the genus and ASV levels (Adonis; p = 0.032 and p = 0.053, respectively Introduction: Patients with relapsing MS (RMS) who show an increased rate of relapse or disability worsening can be described as showing high disease activity (HDA). Treatment with Cladribine Tablets 10 mg [cumulative dose 3.5 mg/kg (CT3.5)] in the CLARITY study, and with CT3.5 added to interferon-b in the ONWARD study demonstrated efficacy vs. placebo (PBO) across a range of patients with active MS. Combining double-blind data from these studies allows assessment of the efficacy of treatment with CT3.5. Objectives: The objective of this post hoc analysis is to compare the effects of CT3.5 vs. PBO on the proportion of patients achieving no evidence of disease activity (NEDA) status in HDA subgroups identified using two sets of criteria in a pooled cohort of patients from CLARITY and ONWARD. Methodology: Patients from CLARITY and ONWARD were retrospectively stratified using 2 sets of HDA criteria based on relapse history, prior treatment, and MRI characteristics: high relapse activity (HRA; N = 314) and HRA plus disease-activity-on-treatment (HRA ? DAT; N = 459). Patients treated with CT3.5 or PBO who fulfilled these criteria and achieved NEDA were compared over 2-years using odds ratios (ORs) and 95% CIs. Results and Conclusions: In the HRA subgroup, 76.5% of CT3.5-treated patients were relapse-free, 86.7% were T1 Gd ? lesion-free vs. 50.7% and 35.8%, respectively, for PBO. In the HRA ? DAT subgroup, 77.6% were relapse-free and 88.8% were T1 Gd ? lesion-free with CT3.5 vs. 53.9% and 40.8%, respectively for PBO. In the HRA and HRA ? DAT subgroups, 42.7% and 41.3%, respectively, of CT3.5-treated patients were disease activity free compared with 9.7%, (OR 6.94, 95% CI 3.67; 13.12, p \ 0.0001) and 13.7% (OR 4.28, 95% CI 2.62; 6.99, p \ 0.0001) respectively, of PBO recipients. In the overall CLARITY ? ONWARD population (including non-HDA patients), the composite NEDA score also favoured CT3. 5 Introduction: The cognitive impairment (CI) has been linked to lesions and atrophy in multiple sclerosis (MS). Optical coherence tomography (OCT) is considered an atrophy and progression marker.
Objectives: Our hypothesis is that OCT parameters could be a biomarker for cognitive impairment in MS. Methodology: 206 patients were enrolled and assessed at baseline and after 1 year. To all patients neuropsychological assessment and OCT were performed. The evaluation included the Brief Repeatable Battery of Neuropsychological Test (BRB-N) and 4 additional executive function tests. Patients were classified in two groups: CI and preserved. The average thickness of the retinal nerve fiber layer (aRNFL) the quadrants, the volume of the macula cube and the ganglion cell layer (GCL) were analyzed. Results and Conclusions: At baseline, a statistical significance was found in the temporal quadrant of the RNFL which was lower in the group of cognitively impaired patients (p \ 0.041). Regarding the assessment 1 year later, a statistical significance reduction of the GCL was found in the patients with CI versus those considered preserved (p \ 0.041 and p \ 0.049). When the changes in CI were analyzed with changes in the OCT parameters, no statistical significance differences were observed. Conclusions: The CI is related to some of the OCT parameters: the temporal quadrant at baseline and the GCL 1 year later. When we analyzed if the change in cognition (from normal to CI) was related to a decrease in OCT parameters we did not observe statistical significance which could indicate that these parameters evolve in a different way. Introduction: Patients with multiple sclerosis manifest several signs and symptoms such as numbness, loss of vision, lack of coordination and gait impairment interfering with their functional mobility, and could be associated with fatigue. Motor imagery, i.e. internal rehearsal/simulation of an action without any evident physical movement, has been used to improve gait in neurological conditions, however, little research has been carried out in patients with multiple sclerosis. Objectives: This study aims to explore the effect of a home-based motor imagery intervention, in the fatigue and functional mobility in patients with multiple sclerosis. Methodology: A single-blind pilot study with a pre--post intervention design. Patients execute the motor imagery home-based during 15 min, three-times-aweek for 4 weeks. Functional mobility and fatigue are assessed pre and post intervention, using the Timed Up and Go and the Modified Fatigue Impact Scale (MFIS), respectively. Assessors are blind to group moment (pre or post). Objectives: This study aims to determine in a hospitalbased cohort of MS patients if there is any relationship between the professional status and cognitive and motor functions. Methodology: The sample is composed by 30 MS patients (24 females and 6 males) attended at our MS Clinic from March 2018 to October 2018. The mean age was 39.93 years (DP = 11.39; variation 31--61 years) and most patients were employed (57%). The most prevalent type of MS was the relapsing-remitting (87%); median EDSS and disease duration were 1.5 (variation 0-6) and 8. Results and Conclusions: Using the criteria of cognitive impairment defined by ''two or more abnormal tests'', it was found that 43% of MS patients were impaired, of whom eight inactive and five active, although the difference was not statistically significant. However, when analyzed the performances by each cognitive test with four t tests for independent groups we ver- Results and Conclusions: Results: We included 11 from 18 NMOSD patients with current follow-up in our center; 9 female, mean age at interview 52 years old (range 23-71). Four patients had positive anti-AQP4 antibodies; 9 had at least one episode of optic neuritis (NO) and 5 had episodes of transverse myelitis (TM) (4 with both NO and TM). Mean result of MoCA test (n = 11) was 21 points (SD 7), mean result of CVLT (n = 11) was 48.7 words (SD 10.5). Mean number of words in verbal fluency was 23.4 (SD 16.4) in categorical type and 14.6 (SD 5.8) in phonemic type. Mean result of BVMT-R (n = 9) was 19.4 (SD 9.0), and mean result of SDMT (n = 8) was 43 (SD 15.6). HADS (n = 9) showed borderline values for anxiety (mean 9.4, SD 4.8) and for depression (mean 8.7, SD 5.1). Mean total MFIS scale (n = 6) result was 43 points (SD 11.7). Discussion: In our cohort, NMOSD patients showed important cognitive impairment and levels of fatigue, not as much depression and anxiety as expected comparing with studies performed in MS patients.
The small number of patients tested is a limitation of our study. In addition, the existence of visual and motor sequels in some patients prevented the completion of all the tests, suggesting that it might be necessary to adapt the tests to this population. Introduction: In CLARITY, patients with high disease activity (HDA) relapsing multiple sclerosis had clinical and magnetic resonance imaging responses to Cladribine Tablets 10 mg [cumulative dose 3.5 mg/kg (CT3.5)] that were generally better than/comparable to the overall CLARITY population. Objectives: Post-hoc analyses to determine lymphopenia rate in patients with HDA in the CLARITY/ CLARITY Extension CT3.5 cohort. Methodology: Patients were retrospectively analysed using two HDA criteria sets: (1) high relapse activity (HRA): C 2 relapses in year before study entry, with/ without disease modifying drug (DMD) treatment. (2) HRA plus disease-activity-on-treatment (DAT): C 1 relapse AND C 1 T1 gadolinium-enhancing or C 9 T2 lesions in year before study entry during treatment with other DMDs. Patients exposed to CT3.5 in Years-1/2 only were the CT3.5 group; the CT7.0 patient group received further courses in Years 3/4. The Adverse Event of Special Interest (AESI) lymphopenia was determined by absolute lymphocyte count (ALC) and lymphopenia from CLARITY/CLARITY Extension. Results and Conclusions: In CT3.5-Year-2, AESIs/100 patient-years were similar in HRA and HRA ? DAT subgroups [11.50 (N = 196); 13.09 (N = 219)], and in corresponding non-HDA groups [14.08 (N = 489); 13.46 (N = 466)]. In CT7.0-Year-4 rates were approximately double to CT3.5-Year-2. Median ALC nadir (9 10 9 /L) for CT3.5-Year-2 HRA and HRA ? DAT were 0.71 and 0.70; median nadirs were 0.65 in corresponding non-HDA subgroups. A similar pattern was seen in CT7.0-Year-4, but with lower nadirs than CT3.5-Year-2. Time to ALC nadir differed slightly between HDA subgroups. Incidence of Grade-3 lymphopenia for CT3.5-Year-2 was similar between HDA and non-HDA subgroups, and for CT7.0-Year-4 was lower in HDA than non-HDA subgroups. Grade-3 lymphopenia incidence was lower in CT3.5-Year-2 than CT7.0-Year-4. Grade-4 lymphopenia incidence was low in all subgroups. No relevant differences existed between HDA and non-HDA groups regarding incidence of AESI lymphopenia, ALC nadir, and time to ALC nadir. Introduction: Disease-modifying therapies (DMT) for multiple sclerosis (MS), especially non-BRACE (Betaseron, Rebif, Avonex, Copaxone, Extavia), raise concerns about infectious risk. Our work analyses the result of a systematic infectious diseases (ID) consultation in a cohort of MS patients before or during treatment with these drugs. Objectives: To understand the importance of ID consultation on patients taking non-BRACE therapies, regarding infectious risk, vaccination strategies and surveillance needs. Methodology: We collected demographic and clinical data from clinical records of MS patients followed in the MS Clinic and ID consultation (2010-2017). Results and Conclusions: 149 patients (107 females) planned to start a non-BRACE DMT (natalizumab, fingolimod, dimethyl fumarate (DMF), teriflunomide or rituximab): 19 naïve, 95 previously on BRACE and 35 already under non-BRACE DMT. Median age was 36 years and disease duration was 7.5 years. A diagnosis of latent tuberculosis (LTB) was elicited in 40 patients and 88% were treated. We found a positive varicella-zoster virus (VZV) IgG or a history of varicella in 133 patients; 80 were immune against hepatitis B virus and 74 to hepatitis A virus. Six patients were vaccinated for VZV; anti-HBV, anti-HAV and anti-pneumococcal vaccines were recommended for those without immunity or previous vaccination. In follow-up, a low CD4
? count prompted Pneumocystis jirovecii chemoprophylaxis in two patients; recurrent genital herpes motivated chemoprophylaxis in 1 patient. Hospital admission was needed in a patient with chickenpox, a patient with pyelonephritis and in a case of cervicitis; all of them recovered. Other non-severe infections reported were: urinary tract infections (17), skin/soft tissue infections (15), respiratory infections (12) and gastroenteritis (3) . In this cohort, we point the high number of LTB diagnosis and the need for its treatment before starting DMT. This study highlights the importance of individualized management as well as the assessment and mitigation of the infectious risk before and even during these therapies. Introduction: Fingolimod prevents lymphocyte egress from lymphoid tissue, thereby reducing CNS autoaggressive lymphocyte infiltration. Objectives: We aimed to study whether the degree of lymphocyte reduction was associated with fingolimod efficacy, measuring clinical and imaging disease outcomes. Methodology: Retrospective data analysis of consecutive MS patients currently under fingolimod in our institution, with complete blood count available at baseline and at 3/6 months, minimum period of 1 year follow-up and available MRI data at 1 year follow-up. Clinical data concerning relapse occurrence, time to relapse, EDSS confirmed progression at 6 months and time to progression was collected from patients' files. Presence of enhancing lesions and T2 lesion load increase at 1 year follow-up MRI was recorded, as well as lymphocyte count at baseline and at 3/6 months. Patients were separated into two groups according to nadir lymphocyte value above/below 500. We analyzed the association between lymphocyte value and clinical/imaging variables using Chi square test. We estimated risk of relapse between groups and risk of disability progression using Cox univariate/multivariate regression and Kaplan-Meier survival analysis with log-rank test. Results and Conclusions: A total of 43 patients were reviewed, 13 excluded due to incomplete data. Twenty-one were female (70%), mean age of 40.3 years (± 8.7) mean EDSS at baseline of 2.8 (± 1.5) and mean duration of disease at baseline of 10 years (± 5.5), with no significant differences found between groups. A nadir lymphocyte count below 500 was not associated with the presence of enhancing lesions (p = 0.32) or T2 lesion load increase (p = 0.23). Nadir lymphocyte count below 500 was not significantly associated with risk of first relapse (HR 1 Introduction: Ocrelizumab, a humanized monoclonal antibody targeting CD20-expressing B cells, was approved in the European Union in January 2018 for the treatment of adult patients with relapsing and primary progressive multiple sclerosis (PPMS). The efficacy and safety of ocrelizumab in PPMS patients were assessed during phase III ORATORIO clinical trial. Objectives: To evaluate the safety, tolerability and effectiveness of ocrelizumab in a real-world clinical setting. Methodology: Prospective longitudinal cohort study of patients with PPMS treated with ocrelizumab at our center. Demographic and clinical characteristics, including Expanded Disability Status Score (EDSS), Timed 25-Foot Walk (T25-FW), 9-Hole Peg Test (9-HPT), Magnetic Resonance Imaging (MRI) data, prior disease modifying therapies, infusion-related reactions and other adverse effects were examined. Results and Conclusions: Twenty-one patients were included, 11 (52.4%) males with a mean age of 46.1 ± 9.1 years. Mean disease duration from symptom onset was 9.1 ± 6.9 years and mean disease duration from diagnosis of PPMS was 5.3 ± 5.9 years. Median pre-treatment EDSS was 3.5 (range 1.5-7.5), mean T25-FW was 17.8 ± 27.7 s and mean 9-HPT (both hands) was 34.1 ± 17.5 s. Four out of 20 (20.0%) patients had gadolinium-enhancing lesions on baseline MRI. Eight (38.1%) patients were treatment-naïve prior to ocrelizumab initiation. Mean follow-up time was 3.7 ± 2.5 months with 6 (28.6%) patients under treatment for at least 6 months. Infusion-related reactions were experienced by 2 (9.5%) patients during one of the first two infusions. Two (9.5%) patients experienced infections during follow-up period. In conclusion, our results show that our PPMS patients are similar to the ORATORIO trial population, with a slightly higher time to treatment from symptom onset and diagnosis. Ocrelizumab appears to be safe in our real-world cohort, with a lower frequency of infusion-related reactions than those reported in the literature. Introduction: Teriflunomide is a once-daily oral medication approved to reduce the annualized relapse rate and the risk of disability progression of relapsing-remitting multiple sclerosis (MS). Objectives: To characterize the population treated with teriflunomide in a tertiary MS Clinic and the safety and efficacy profiles of this drug. Methodology: We collected clinical data from patients treated with teriflunomide between December 2015 and December 2018 regarding demographic characteristics, treatment background, efficacy and safety data. Results and Conclusions: We included 52 patients (33 female). Median age at teriflunomide initiation was 47 years-old (IQR 11; no differences between gender) with a median time from diagnosis to treatment of 11 years (IQR 12). Regarding previous MS treatments, 34 patients had been treated with interferon, 12 with glatiramer acetate, 5 with dimethyl fumarate, 3 with natalizumab and 10 patients were treatment naïve. The main reasons for initiating teriflunomide were patient preference (n = 29) and adverse events of ongoing medications (n = 16). There were no differences in EDSS measures at 3 and 6 months posttreatment comparing to the baseline (median EDSS 1.5 at all time points). Main adverse effects were gastrointestinal complaints (n = 13, 25%), hair weakening (n = 10, 19%) and skin reactions (n = 6, 12%). Treatment was stopped in 17 patients (33%) due to gastrointestinal complaints (n = 4), skin/hair effects (n = 4), increase of liver enzymes (n = 4) or other causes (n = 5). Consistent with other studies, teriflunomide was initiated at a median age of 47 years old, yet without differences in age between gender, and the majority of patients had tried another first line treatment. The proportion of adverse effects leading to drug discontinuation seems to be higher than reported in the literature. We highlight the importance of patient information and the need to accomplish the recommendations regarding clinical and analytical monitoring. Introduction: scIFNb-1a reduces relapse rates and delays disability progression in patients with multiple sclerosis (MS). Objectives: This post hoc analysis of scIFNb-1a-treated patients from the PRISMS study examines the association of Year (Y) 1 MAGNIMS score on time to CDA event and disease progression. Methodology: In PRISMS-2, relapsing-remitting MS patients were randomized to scIFNb-1a 22 or 44 lg, or placebo, three times weekly for 2 years. Placebo patients were randomized to scIFNb-1a 22/44 lg at Y3. Patients were followed to Y15 post-randomization (22 lg n = 95; 44 lg n = 95; placebo n = 100). We Introduction: Several studies revealed lower multiple sclerosis relapse rates during pregnancy. Diseasemodifying therapies are generally avoided during this period.
In 2010 a 19-year-old woman with no relevant past history presented to emergency department with left hemiparesis, dysphagia, mild dysphonia and left limbs dysmetria. CSF analysis revealed mild pleocytosis, normal glycose and protein levels, unmatched oligoclonal bands and negative infectious study. Brain MRI confirmed multiple subcortical, periventricular and infratentorial white matter lesions. Nine months later new hemispheric T2 white matter lesions were apparent on brain MRI, some with gadolinium enhancement. Accordingly, the diagnosis of relapsing-remitting multiple sclerosis was admitted, but she refused treatment initiation. After a spinal cord relapse, she started treatment with interferon b-1a; however, 5 years later, treatment was interrupted due to twin pregnancy. She experienced no relapses during gestation (EDSS 1) and refused to resume treatment (including intravenous immunoglobulin) during lactation (12 months), despite a new relapse during puerperium. She is currently pregnant again and clinically stable (EDSS 1). The opposite clinical scenario occurred in a 27-yearold woman admitted after several episodes of right hemisensory loss and ipsilateral limbs motor deficit. CSF analysis was unremarkable apart from unmatched oligoclonal bands. T2-weighted brain and spinal cord MRI showed widespread periventricular, subcortical and infratentorial white matter hyperintense lesions. Assuming the diagnosis of relapsing-remitting multiple sclerosis, treatment with interferon b-1a was started. Due to ongoing disease activity, it was switched to natalizumab 3 years later, achieving disease stability (EDSS 1, stable lesion burden) during the next year. Therefore it was decided to stop immunomodulatory therapy in order to get pregnant. During pregnancy she experienced several relapses (EDSS 4). She resumed treatment with natalizumab shortly after giving birth, as she continued experiencing relapses. Introduction: Neuropsychiatric lupus occurs in up to 40% of systemic lupus erythematosus (SLE) patients. However, central nervous system involvement in SLE patients may occur as a result of other autoimmune conditions, such as anti-NMDA receptor autoimmune encephalitis or neuromyelitis optica spectrum disorders (NMOSD). Methodology: A 41-year-old male came to our attention complaining of shock-like pain in his limbs, numbness in his legs and mild urinary incontinence. His prior medical history included: Buerger's disease, treated with sympathectomy; SLE, diagnosed 6 years prior in the context of migratory arthralgias, fatigue, oral ulcers, positive ANA, anti-dsDNA and Coombs test, low complement and hypergammaglobulinemia; and recently diagnosed interstitial lung disease. He was treated with hydroxychloroquine 400 mg/day and folate. His neurological examination showed preserved higher functions, no involvement of cranial nerves, mild paresis of his left arm and both legs, pinprick and vibratory hypesthesia in his lower limbs and left C5-C8 dermatomes, with globally brisk reflexes. Neuraxis magnetic resonance imaging (MRI) showed no brain lesions (including double inversion recovery sequences) and extensive myelitis showing disperse, mainly peripheral, hyperintense T2 lesions with gadolinium enhancement (C2, C7, D1-D3, D6-D8 and D11). Cerebrospinal fluid analysis showed mild inflammation (8 cells/mm 3 ) and negative oligoclonal bands. Intravenous methylprednisolone was started with partial symptom resolution and patient was maintained on a steroid taper and pregabalin. Azathioprine was introduced later when positivity for anti-AQP4 antibodies was known. At his last appointment, MRI showed resolution of spinal cord T2 hyperintensities. However, the patient maintained paroxysmal tonic spasms, ameliorated by a second course of steroids. Introduction: Antibodies against myelin oligodendrocyte glycoprotein (MOG) have been described in neuromyelitis optica spectrum disorders, multiple sclerosis, acute disseminated encephalomyelitis and, less frequently, in viral encephalitis. Methodology: Case 1: A 6-year-old boy was admitted due to diplopia. Two weeks earlier he was diagnosed with acute sinusitis and treated with amoxicillinclavulanate. On admission, he presented diplopia, right sixth nerve palsy, and bilateral papilledema. Blood workup showed leukocytosis and a CRP of 83 mg/L. CSF: 17 leukocytes/mm 3 , normal glucose and protein. Brain CT showed bilateral white matter hypointensities. Presumptive treatment with aciclovir and ceftriaxone was started. Brain MRI (day 2) revealed hyperintensity lesions (T2 and FLAIR) on fronto-temporo-parieto-occipital regions, thalamus and brainstem, some were contrast-enhancing.
Methylprednisolone pulse therapy was started with success. A later MR angiography raised the hypothesis of post-vasculitis lesions. MOG antibodies were positive (antiAQP4-neg and negative oligoclonal bands). Case 2: A 16-year-old female, was admitted due to headache, nausea and loss of vision. Initial workup, including blood workup and brain CT were normal. Some days later she started vomiting and presented ataxia and a pyramidal syndrome. Brain MRI showed large T2/FLAIR cortico-subcortical and pontine hyperintense and contrast-enhanced lesions, and an hyperintense optic chiasm lesion. Spinal MRI revealed several enhancing lesions. VEPs: bilateral decreased amplitude and increased latency. CSF: 20 leukocytes/mm 3 , glucose and protein were normal. MOG antibodies and oligoclonal bands were positive (antiAQP4-neg).
Methylprednisolone therapy (5 days, 1 g/day), oral prednisolone and rituximab were prescribed with gradual recovery. During steroid tapering, motor deficits worsened and intravenous immunoglobulin was started with improvement. Results and Conclusions: We present two illustrative cases of the wide spectrum of anti-MOG antibody disease. A positive response to immunosuppression is remarkable. However, there are reports in the literature of a high incidence of relapses during steroid taper, as in case 2. Specific pediatric treatment protocols are necessary for better therapeutic management. cases is valuable as information for its specific features is still very limited. Case Report: 50-year-old man, with a concurrent history of diabetes and arterial hypertension presented a clinical presentation with a two-week course of gait imbalance, numbness in abdomen and lower members and urinary retention which had been preceded by influenza-like prodromal symptoms. On neurological examination, there was a prominent flaccid tetraparesis and a upper thoracic level by T4. Cerebrospinal fluid showed mononuclear pleocytosis (440 cells/lL) and elevated protein concentration. Other laboratory tests, including extensive viral serologies were otherwise normal/negative. MRI spine demonstrated a longitudinally extensive T2 hyperintensity running in the superior-inferior direction from the conus to bulbomedullary transition on sagittal images. Brain MRI disclosed a few periventricular lesions inconsistent with ADEM. None of the lesions demonstrated gadolinium enhancement. He was administered high-dose intravenous methylprednisolone (1 g/day, 8-day course) with significant improvement and functional recovery. After initiation, a MOG-IgG seropositivity was identified and 5 months after he did not experience any relapses. Introduction: Optic neuritis may evolve into multiple sclerosis and MRI demonstrates lesions in optic nerves. Objectives: To study MRI of optic nerves. Methodology: Patients with recurrent optic neuritis (ON) with a good recovery and transverse myelitis (TM) were followed from 2000 to 2015, 10 years of disease and EDSS \ 3, were classified as ''benign'' with a recurrent optic spinal phenotype multiple sclerosis (OSMS). A prospective population study was performed on 16 patients OSMS. All patients was negative (AQP4)-IgG and negative (MOG)-IgG. Most patients showed brain and spine lesions met MAG-NIMS criteria (2016). For lesions on MRI in sequence, STIR with the optic nerves were divided into three segments: intra-orbital (IO) (25 mm: the longest segment and communication between subarachnoid space around the optic nerve that in suprasellar cistern, canalicular (CAN) (9 mm: as through optic canal and prechiasmatic and chiasmal (CHI) (16 mm: intracranial segment in suprasellar cistern). Results and Conclusions: 2 (12.5%) patients showed normal optic nerves. Lesions on MRI the optic nerves in 9 (56.25%) patients with lesion unilateral, 5 (31.2%) patients with lesions bilateral, 14 (87.5%) patients with lesion intra-orbital (IO), 7 (43.7%) showed lesion CAN, 14 (87.5%) IO and 1(6.2%) patient showed lesion prechiasmatic. No patient showed contrast enhancement. Patients with recurrent ON and TM, at least 10 years of disease and low EDSS indicate that optic spinal recurrent phenotype of MS and not a NMO spectrum syndrome. Most patients did not have extensive lesions in optic nerves and visual event good recovery could be classified as a subgroup of MS with a benign course. Methodology: Retrospective and descriptive study. In the cohort of patients with recurrent optic neuritis and transverse myelitis were followed from 2000 to 2016 in Hospital Lagoa and Hospital Gafrée Guinle (Rio de Janeiro, Brazil). The OS-MS patients were selected patients did not meet criteria to the NMO (2006). At least one brain and one spinal cord MRI for each patient was analysed by two neuroradiologists to evaluate images (blind study). We analysed the following clinical variables and laboratory data, duration of disease and classification of lesions observed by MRI. The MS criteria (2016) and NMO spectrum disorder (NMOSD) (2015) were applied. Results and Conclusions: In 41 patients, only 27 were included, because no have requisitions the search. In OS-MS patients sample of 27 patients, the majority female and white, mean age at onset 29. Introduction: Multiple sclerosis (MS) is a chronic demyelinating neurological disease primarily affecting young adults, with a prevalence of approximately 0.1% in the Caucasian population. In recent years some studies have raised concern over the possibility of misdiagnosis in MS, which could be as high as 6%, particularly among patients with primary progressive MS. Several single gene disorders share clinical and radiologic characteristics with MS, and have the potential to be overlooked in the differential diagnostic evaluation of both adult and pediatric patients. Diagnosis of primary progressive MS has special challenges as there are no relapses and the MRI findings are different from those patients with relapsing onset MS. Clinically primary progressive MS is similar to spastic paraparesis like hereditary spastic paraparesis or other metabolic disorders, such as lysosomal storage disorders, mitochondrial diseases or neurometabolic disorders, presenting with this predominant symptom. Objectives: The overall aim of our research project is to develop a Next Generation Sequencing strategy to identify metabolic disorders in 104 patients with a presumptive diagnosis of primary progressive MS. Introduction: Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease that affects the neurons of the central nervous system. Activated T cells, specific for myelin epitopes, cross the brain barriers, and react against the myelin sheath, leading to demyelination. Objectives: Since T cells are generated within the thymus, here we explored, in mice, the alterations occurring in this organ throughout the different phases of the disease. Methodology: We induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 females and sacrifice them at the onset (day 16) and chronic phases of disease (day 23), along with non-induced controls. Results and Conclusions: We observed thymic atrophy in EAE mice at the onset that remained until the chronic phase of disease. This atrophy was associated with a preferential loss of the CD4
? CD8 ? double positive thymocytes, an intermediate population between the more immature CD4
-CD8 -double negative and the most mature single positive thymocytes. This was accompanied by an increase in the thymic medullary/cortical ratio and by an altered expression levels of genes important for T cell survival. During the chronic phase, the thymi remained atrophic, but reacquired the normal proportion of the main four thymocyte populations and the normal medullary/cortical ratio. Importantly, at the onset phase, and accompanying these thymic alterations, EAE animals presented an increased percentage of demyelinating lesion area in the cerebellum, and an increased expression of interferon gamma (Ifng), interleukin (Il) 12a, and Il17a. This study suggests dynamic thymic alterations occurring in response to EAE, from the induction to the chronic phase, that might help to elucidate the MS pathophysiology. Introduction: Neurosarcoidosis is a rare neuro-inflammatory disorder with protean manifestations which presents a diagnostic challenge. Objectives: We describe an atypical presentation of neurosarcoidosis, with cerebrospinal fluid (CSF) and histopathological findings. Methodology: A 40-year-old woman with a 5-month history of fatigue, intermittent fever, skin lesions, lymphadenopathies and arthralgias presented with a rapidly progressive course of confusion and altered behaviour. On admission she was restless, disoriented, with disorganized speech, but without focal neurological deficits or meningism. Later she became very agitated requiring sedation, intubation and admission to the intensive care unit (ICU). A presumptive diagnosis of viral encephalitis was made, and the patient was started on intravenous acyclovir. Brain CT and contrast-enhanced MRI were normal. CSF analysis showed lymphocytic predominant pleocytosis, hyperproteinorrachia and one oligoclonal band. FDG-PET revealed increased FDG uptake of axillary, hilar, inguinal and iliac lymph nodes. An inguinal lymph node biopsy showed histopathological findings of non-caseating granuloma without evidence of malignant cells or infection, supporting the diagnosis of sarcoidosis. Mildly increased levels of serum angiotensin-converting enzyme were found. Extensive CSF and serum studies were negative for infectious diseases, particularly for tuberculosis, malignancy and other autoimmune causes. The patient was started on 300 mg of hydrocortisone for 8 days with a subsequent 2 months oral prednisolone taper with complete recovery. Two months after completing treatment she presented with erythematous lesions on the shin, leg and forearm that were clinically suggestive of erythema nodosum. She initiated treatment with hydroxychloroquine with complete resolution of skin lesions. Results and Conclusions: We report a case of severe aseptic encephalitis requiring ICU admission as the first manifestation of neurosarcoidosis in a patient without a previous diagnosis. CSF examination revealed a neuro-inflammatory process. FDG-PET identified a target for biopsy, which allowed Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small vessel disease, manifesting as recurrent stroke, migraine with aura, behavioural and cognitive disturbances. In early stages, CADASIL may be misdiagnosed as multiple sclerosis (MS). Although these two distinctive diseases are not known to co-occur, there are cases of CADASIL with an inflammatory-like presentation, including optic neuritis and spinal cord involvement that can perfectly mimic MS. Objectives: Case Report. Methodology: A 25-year-old man started an acute right sensorimotor loss with complete remission within a few days. He has maternal family history of depression, dementia and MS. All autoimmune and infectious diseases were excluded, oligoclonal bands, aquaporin 4 antibody and visual evoked potentials (VEP) were negative/normal. Brain MRI depicted hyperintense lesions at splenium of corpus callosal, left subcortical frontal lobe and periventricular temporal lobe, without gadolinium enhancement or diffusion restriction. Three years later, his 53-year-old mother performed a brain MRI due to complaints of migraine and cognitive impairment that depicted white matter abnormalities suggestive of CADASIL and a pathogenic Notch3 mutation was identified. Our patient was later confirmed to be a carrier as well. At 32 years-old, he developed left eye pain and visual loss; VEP revealed prolonged latency on left eye. He started corticotherapy with good response. At this point, CSF oligoclonal bands and plasma aquaporin 4 antibody remains negative, but brain and spinal MRI showed new T2-hyperintense lesions on left optic nerve and in multiple cervical and dorsal spinal segments suggestive of an inflammatory pattern, fulfilling criteria of temporal and spatial dissemination for MS. Introduction: Multiple sclerosis (MS) is the most frequent inflammatory demyelinating CNS disease, with most cases occurring sporadically. Some patients have a first, second or third degree relative also affected by MS, being considered as familial MS. Objectives: Our aim was to characterize our cohort of patients with familial MS. Methodology: A retrospective analysis of a MS patients cohort, followed in a Portuguese tertiary center, with at least two affected patients in the same family (related in first degree) was performed.
Results and Conclusions: From a cohort of 655 MS patients, we found a total of 11 families with 2 affected relatives (total of 22 patients). Five families were constituted by a pair of siblings, and the other 6 by a parent-child pair. Patients had an average age of 44 years, 60% being man. Eighteen patients had relapsing-remitting MS, 3 had secondary progressive MS, 1 had primary progressive MS and 1 had a clinically isolated syndrome. Mean age at onset was 31-years-old. In the 6 families represented by 2 generations, mean age of onset was 42 years-old in the parents, and 25 years-old in the successive generation. HLA analysis was performed in 18 patients (7 families), with both affected members of each family having at least one haplotype in common. The most common genetic findings were HLA-DRB1*13 allele (7 patients) and HLA-DRB1*15 allele (6 patients). Only 1 patient had another auto-immune disease. Mean EDSS at the last observation was 3, with an average follow-up of 11 years. In our cohort, second generation patients seemed to have a lower age at the onset of the disease. Some authors have previously described this finding. Introduction: Multiple sclerosis (MS) diagnosis is one of exclusion. Several entities can mimic it. One example is Cerebral Autosomal Dominant Arteriopathy and Subcortical Ischemic Leukoencephalopathy (CADASIL), featuring significant white matter abnormalities and neurologic dysfunction. Objectives: To review three cases of NOTCH3 mutations in patients with an MS diagnosis. Methodology: Next Generation Sequencing using a custom mitochondrial gene panel with around 250 genes involved in mitochondria and lysosomal metabolism. Libraries were prepared using SureSelect QXT target enrichment system from Agilent. Results and Conclusions: Case 1: Female, 62 years-old, followed since 2003 for unspecific neurologic symptoms and white matter lesions, interpreted as MS. In 2011 a diagnostic revision was made and a family history of early dementia was disclosed. Genetic testing and skin biopsy confirmed a CADASIL diagnosis. Case 2: Female, 58 years-old, diagnosed with MS at 28 when she presented with vertigo. Oligoclonal bands were negative and brain MRI showed periventricular and subcortical hyperintensities. She was treated with interferon beta 1a and remained stable. The diagnosis was reviewed in 2011. There was a history of headaches and genetic testing described a novel NOTCH3 mutation in exons 3 and 32. Case 3: Male, 58 years-old, had an episode of leftsided hemiparesis and paresthesia in 1994, interpreted as an MS relapse. Since 2005 he started showing depressive symptoms and cognitive decline. Spinal cord MRI was normal and brain MRI showed extensive white matter lesions. Genetic testing performed in 2009 showed no mutations in the hotspot exons of NOTCH3. In 2017 he had an ischemic stroke. Genetic testing was extended to all exons of NOTCH3, and a novel mutation in exon 6 was found. The authors aim to shed light on 3 cases of prolonged MS misdiagnosis, later redefined as CADASIL. This distinction is many times challenging and a continuous effort to rethink a given diagnosis is recommended. Funding: No funding or sponsorship was received for this research. Keywords: CADASIL; Multiple sclerosis structural quality. The supplement was then peer reviewed by an Editorial Board Member of Neurology and Therapy, independent of the meeting's abstract submission process.
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